Marinus Pharma (MRNS) Reports Ganaxolone Phase 1 Achieves Dose Levels Targeted for Efficacy in SE
Tweet Send to a Friend
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that in its Phase 1 dose-escalation study, ganaxolone intravenous (IV) achieved dose levels targeted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
